Search clinical trials for: Surufatinib

Total 98 results

1
2
›

Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Hutchison Medipharma Limited

Completed

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchmed

Completed

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Tumors

United States, Italy
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (CRC-C1721)

Relative Bioavailability

China
Hutchmed

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
Hutchison Medipharma Limited

Completed

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Hutchmed
BeiGene

Active, not recruiting

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors | Metastatic Solid Tumor | Anaplastic Thyroid Cancer

United States
Hutchison Medipharma Limited

Unknown

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Biliary Tract Cancer

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaborators

Not yet recruiting

Surufatinib in G3 Neuroendocrine Tumors

Neuroendocrine Tumor Grade 3
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Biliary Tract Carcinoma
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Healthy

United States
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Head and Neck Cancers - Salivary Gland

China
Changhai Hospital

Not yet recruiting

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor

China
Fudan University

Not yet recruiting

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult
Fudan University

Recruiting

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China
Hutchmed

No longer available

Expanded Access Program of Surufatinib

Neuroendocrine Tumors

United States
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sarcoma

China
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
RenJi Hospital

Not yet recruiting

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Gastric Cancer | Pancreas Cancer | Biliary Tract Cancer | ESCC

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma

Unresectable Biliary Tract Carcinoma
Fujian Cancer Hospital

Recruiting

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Advanced Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Hutchmed

Completed

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Lymphoma | Osteosarcoma | Solid Tumor | Ewing Sarcoma | Rhabdomyosarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Pancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hubei Cancer Hospital

Recruiting

Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

Colorectal Neoplasms

China
Sun Yat-sen University

Recruiting

A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer

Gastric Adenocarcinoma

China
Wuhan Union Hospital, China

Not yet recruiting

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Unresectable Advanced Solid Tumors | Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Zhejiang Cancer Hospital

Suspended

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Biliary Tract Cancer
Wuhan Union Hospital, China

Not yet recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Sun Yat-sen University

Recruiting

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms

China

1
2
›

3

Subscribe